NASDAQ:PRLD - Prelude Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $44.00
  • Forecasted Upside: 202.41 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$14.55
▼ -0.21 (-1.42%)

This chart shows the closing price for PRLD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Prelude Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRLD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRLD

Analyst Price Target is $44.00
▲ +202.41% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Prelude Therapeutics in the last 3 months. The average price target is $44.00, with a high forecast of $61.00 and a low forecast of $20.00. The average price target represents a 202.41% upside from the last price of $14.55.

This chart shows the closing price for PRLD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Prelude Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/13/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/13/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2021BarclaysLower Price TargetOverweight$33.00 ➝ $20.00High
11/15/2021HC WainwrightReiterated RatingBuy$61.00High
10/8/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight$60.00 ➝ $35.00Low
10/8/2021HC WainwrightReiterated RatingBuy$62.00High
10/8/2021BarclaysLower Price TargetOverweight$80.00 ➝ $33.00High
7/27/2021Bank of AmericaUpgradeNeutral ➝ Buy$60.00High
4/26/2021HC WainwrightInitiated CoverageBuy$62.00High
3/17/2021Morgan StanleyBoost Price TargetEqual Weight$47.00 ➝ $60.00Low
3/9/2021BarclaysInitiated CoverageOverweight$80.00High
12/16/2020Morgan StanleyBoost Price TargetEqual Weight$38.00 ➝ $47.00Medium
11/20/2020Bank of AmericaDowngradeBuy ➝ NeutralHigh
11/12/2020Morgan StanleyBoost Price TargetEqual Weight$34.00 ➝ $38.00Low
10/20/2020Bank of AmericaInitiated CoverageBuy$40.00High
10/20/2020Morgan StanleyInitiated CoverageEqual Weight$34.00High
10/20/2020The Goldman Sachs GroupInitiated CoverageNeutral$37.00High
(Data available from 12/9/2016 forward)

News Sentiment Rating

0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/13/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/10/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/10/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
12/9/2021

Current Sentiment

  • 2 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Prelude Therapeutics logo
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; and PRT-K4 that is in preclinical stage for solid tumors. Prelude Therapeutics Incorporated was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Read More

Today's Range

Now: $14.55
Low: $14.34
High: $15.22

50 Day Range

MA: $20.11
Low: $13.60
High: $35.50

52 Week Range

Now: $14.55
Low: $13.03
High: $95.38

Volume

247,688 shs

Average Volume

294,715 shs

Market Capitalization

$686.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44

Frequently Asked Questions

What sell-side analysts currently cover shares of Prelude Therapeutics?

The following Wall Street research analysts have issued reports on Prelude Therapeutics in the last twelve months: Bank of America Co., Barclays PLC, HC Wainwright, Morgan Stanley, and Zacks Investment Research.
View the latest analyst ratings for PRLD.

What is the current price target for Prelude Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Prelude Therapeutics in the last year. Their average twelve-month price target is $44.00, suggesting a possible upside of 202.4%. HC Wainwright has the highest price target set, predicting PRLD will reach $61.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $20.00 for Prelude Therapeutics in the next year.
View the latest price targets for PRLD.

What is the current consensus analyst rating for Prelude Therapeutics?

Prelude Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRLD will outperform the market and that investors should add to their positions of Prelude Therapeutics.
View the latest ratings for PRLD.

How do I contact Prelude Therapeutics' investor relations team?

The company's listed phone number is 302-467-1280 and its investor relations email address is [email protected] The official website for Prelude Therapeutics is www.preludetx.com.